Excipient Market Overview: Clariant sets up its first PEG excipients facility in US; India harmonizes 22 excipient monographs

DATA COMPILATION
#PharmaFlow

Pipeline Prospector March 2026 highlights: Lilly to acquire Centessa for US$ 7.8 bn; Merck buys Terns Pharma for US$ 6.7 bn

Stock Recap
#PipelineProspector

LIDOSITE TOPICAL SYSTEM KIT-1

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

79 API Suppliers, 13 USDMF, 11 CEP/COS, 3 JDMF, 7 EU WC, 15 KDMF, 27 NDC API, 38 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

13 Drugs in Development

13 Drugs in Development

FINISHED DOSAGE FORMULATIONS

698 FDF Dossiers, 232 FDA Orange Book, 334 Europe, 67 Canada, 17 South Africa, 48 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - 4%, INJECTABLE;INJECTION - 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 20% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 4% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 0.005MG/ML;0.5%, INJECTABLE;INJECTION - 0.005MG/ML;1%, INJECTABLE;INJECTION - 0.005MG/ML;1.5%, INJECTABLE;INJECTION - 0.005MG/ML;2%, INJECTABLE;INJECTION - 0.01MG/ML;1%, INJECTABLE;INJECTION - 0.01MG/ML;2%, INJECTABLE;INJECTION - 0.02MG/ML;2%, INJECTABLE;INJECTION - 0.5%, INJECTABLE;INJECTION - 1%, INJECTABLE;INJECTION - 1.5%, INJECTABLE;INJECTION - 2%, INJECTABLE;INJECTION - 1%, INJECTABLE;INJECTION - 2%, INJECTABLE;INJECTION - 1%, INJECTABLE;SPINAL - 5%, JELLY;TOPICAL - 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 0.02MG BASE/ML;2%, INJECTABLE;INJECTION - EQ 0.01MG BASE/ML;2%

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Evonik, 6 Rochem International Inc, 12 SPI Pharma, 1 PMC Isochem, 1 Pharm-RX Chemical, 1 Boai NKY Pharmaceuticals Ltd, 3 Gangwal Healthcare, 18 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 1 Capital Farma, 15 Kirsch Pharma, 11 Dr. Paul Lohmann GmbH & Co. KGaA, 1 ACG Worldwide, 22 Actylis, 3 Aeon Procare, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 43 BASF, 1 Bioplus Life Sciences, 1 BioSpectra, 5 CD Formulation, 1 Clariant, 17 Corel Pharma Chem, 3 Doshion Polyscience, 2 Esteem Industries, 5 Finar, 13 Gangwal Chemicals, 3 Gloria Interchem, 3 Ideal Cures, 2 Ingredion Pharma Solutions, 10 Kerry, 1 Keval Exports, 4 Kima Chemical, 6 Lonza Capsugel, 9 Lubrizol Life Science Health, 9 Microlex e.U, 3 Nanjing Bold Chemical, 1 Neelkanth MineChem, 2 Nippon Fine Chemical, 2 Nomisma Healthcare, 2 Novo Excipients, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 21 Roquette, 25 Seppic, 3 Shandong Focus Biotechnology Co., Ltd, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 4 Sigachi Industries, 2 Symrise, 3 The Dow Chemical Company, 2 Valens Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

77 Topical, 66 Solubilizers, 48 Thickeners and Stabilizers, 46 Coating Systems & Additives, 45 Parenteral, 37 Fillers, Diluents & Binders, 36 Emulsifying Agents, 29 Controlled & Modified Release, 25 Film Formers & Plasticizers, 25 Surfactant & Foaming Agents, 18 API Stability Enhancers, 18 Granulation, 18 Taste Masking, 17 Direct Compression, 13 Lubricants & Glidants, 13 Co-Processed Excipients, 10 Rheology Modifiers, 8 Chewable & Orodispersible Aids, 7 Disintegrants & Superdisintegrants, 5 Empty Capsules, 4 Vegetarian Capsules, 2 Coloring Agents, 1 Soft Gelatin

DIGITAL CONTENT

3 Data Compilation #PharmaFlow, 65 News #PharmaBuzz

GLOBAL SALES INFORMATION

34 US Medicaid Prescriptions, 25 Regulatory FDF Prices

MARKET PLACE

58 APIs, 15 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 US Patents

4 US Patents

REF. STANDARDS & IMPURITIES

1 EDQM

1 EDQM

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
31/03/2026	Swati Spentose	India	Daeshin Muyak Co., Ltd.	20200108-210-J-409	Lidocaine hydrochloride	2020-01-08	Swati Spentose Private Limited (Unit-I)	India	Plot No. - A-1/2102, 2103 & A-2/2120, Phase III, GIDC, Vapi - 396 195, Dist. - Valsad, Gujarat State, INDIA.
31/03/2026	Delta Synthetic Co. Ltd	Taiwan	Medipoem Co., Ltd.	20210309-210-J-704(12)	Lidocaine hydrochloride	2026-03-18	Delta Synthetic Co., Ltd.	Taiwan	15, Minsheng St., Tucheng Dist., New Taipei City 23679, Taiwan, ROC

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

LIDOSITE TOPICAL SYSTEM KIT-1

LIDOSITE TOPICAL SYSTEM KIT-1

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

79 API Suppliers

13 USDMF

11 CEP/COS

3 JDMF

7 EU WC

15 KDMF

27 NDC API

38 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

13 Drugs in Development

FINISHED DOSAGE FORMULATIONS

698 FDF Dossiers

232 FDA Orange Book

334 Europe

67 Canada

17 South Africa

48 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - 4%

INJECTABLE;INJECTION - 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 20% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 4% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 0.005MG/ML;0.5%

INJECTABLE;INJECTION - 0.005MG/ML;1%

INJECTABLE;INJECTION - 0.005MG/ML;1.5%

INJECTABLE;INJECTION - 0.005MG/ML;2%

INJECTABLE;INJECTION - 0.01MG/ML;1%

INJECTABLE;INJECTION - 0.01MG/ML;2%

INJECTABLE;INJECTION - 0.02MG/ML;2%

INJECTABLE;INJECTION - 0.5%

INJECTABLE;INJECTION - 1%

INJECTABLE;INJECTION - 1.5%

INJECTABLE;INJECTION - 2%

INJECTABLE;INJECTION - 1%

INJECTABLE;INJECTION - 2%

INJECTABLE;INJECTION - 1%

INJECTABLE;SPINAL - 5%

JELLY;TOPICAL - 2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 0.02MG BASE/ML;2%

INJECTABLE;INJECTION - EQ 0.01MG BASE/ML;2%

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Evonik

6 Rochem International Inc

12 SPI Pharma

1 PMC Isochem

1 Pharm-RX Chemical

1 Boai NKY Pharmaceuticals Ltd

3 Gangwal Healthcare

18 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

1 Capital Farma

15 Kirsch Pharma

11 Dr. Paul Lohmann GmbH & Co. KGaA

1 ACG Worldwide

22 Actylis

3 Aeon Procare

3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

43 BASF

1 Bioplus Life Sciences

1 BioSpectra

5 CD Formulation

1 Clariant

17 Corel Pharma Chem

3 Doshion Polyscience

2 Esteem Industries

5 Finar

13 Gangwal Chemicals

3 Gloria Interchem

3 Ideal Cures

2 Ingredion Pharma Solutions

INJECTABLE;INJECTION - 1% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - 2% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - 20% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - 4% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

JELLY;TOPICAL - 2% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons